UNSPSC 51132242: Calcium/ergocalciferol/salicylamide

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN103. This VA Drug Class (CN103) classifies this compound as belonging to the group NON-OPIOID ANALGESICS.

UNSPSC 51132242 Calcium/ergocalciferol/salicylamide is a Commodity code that in practice encompasses a broader range of pharmaceutical and health-supply procurement than its nominal name suggests. State and local governments buying under this code are actually procuring naloxone and drug deactivation systems, generic multi-source pharmaceuticals and over-the-counter products, and related pharmacy benefit program solutions to support community health, public safety, and employee health plan objectives. Issuing bodies include county health departments, state health and human services agencies, and cooperative purchasing alliances serving multiple state and local jurisdictions — Seminole County, Florida; the Texas Health and Human Services Commission; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) represent the recent activity mix. The code shows little internal coherence to its nominal scope; recent opportunities under it are pharmaceutical procurement and supply-chain management, not calcium or vitamin D products as the code name implies.

Activity clusters in Florida and the upper Midwest with some multistate reach through cooperative vehicles. Representative recent solicitations include Seminole County's IFB 60459723LAS for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, due July 26, 2023; the Texas Health and Human Services Commission's Request for Information HHS0017013 for direct-to-manufacturer pharmacy benefit program vendor capabilities, posted April 3, 2026; and the Minnesota Department of Administration's MMCAP Request for Proposal S1070000015802 for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon, with proposals due March 26, 2026. The MMCAP solicitation requires cGMP certification, Drug Supply Chain Security Act compliance, relationships with authorized wholesalers AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson, and evaluation weighted 75 percent on price competitiveness with secondary criteria for administrative compliance and EDI capability.